Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
Status:
Withdrawn
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the utility of secretin-enhanced MRI (S-MRI) in detecting
and measuring pancreatic lesions in patients with known adenocarcinoma or Intraductal
papillary mucinous neoplasm (IPMN) lesions. The hypothesis is that S-MRI is superior to MRI
without secretin enhancement (N-MRI) in increasing tumor conspicuity, allowing for improved
identification and more accurate measurement of lesions or precursor lesions in the pancreas.